The reduced rate will still be almost 10 times the average monthly out-of-pocket costs paid by commercially insured patients.

A third fatality has been recorded among patients receiving treatment with a Sarepta gene therapy, adding to the troubles being faced by the company.

Bristol Myers Squibb (NYSE:BMY) announced on Friday that its anemia therapy, Reblozyl, developed with Merck (NYSE:MRK), did not meet the main goal in a Phase 3 trial for certain adults with a rare ...

Sino Biopharma will acquire LaNova Medicines, which has licensed cancer drugs for Merck and AstraZeneca, for $951 million.

The direct-to-consumer (DTC) platform – called Eliquis 360 Support – will offer Eliquis (apixaban) to patients who pay for ...

Merck & Co. faces headwinds despite being labeled an undervalued stock. Morgan Stanley recently lowered its price target to ...

Pfizer, in partnership with Bristol Myers Squibb, has launched a direct-to-patient sales strategy for Eliquis®, aiming to ...

Health-care companies fell after a lackluster round of earnings. Shares of medical-device maker Abbott Labs shares tumbled by more than 8% after it trimmed and narrowed its 2025 growth projections ...

The health sector is witnessing notable developments. Bristol Myers and Pfizer are offering Eliquis at a discounted rate.

Bristol Myers and Pfizer said on Thursday they will start selling their blockbuster blood thinner, Eliquis, directly to ...

Apixaban would still cost patients 9 times more through the Eliquis 360 Support program than with commercial insurance.

GE Aerospace raised its full-year earnings outlook and beat expectations on its top and bottom lines in the second quarter. PepsiCo said its business remained resilient during the second quarter, ...